Cell MedX Corp., a biotech company, discovers, develops, and commercializes therapeutic and non-therapeutic products for patients with diabetes, Parkinson's disease, high blood pressure, neuropathy, and kidney functions. It develops and manufactures eBalance Pro System for professional use by healthcare practitioners in a clinical setting; and eBalance Home System for home use for general wellness and pain management treatment, which are controlled by the eBalance Console that acts as the central controller for three pre-programmed microcurrent algorithms, including wellness, pain management, and dual. The company also develops eBalance Home and eBalance Pro System for temporary relief of shoulder, waist, back, neck, arms, and legs. The company was formerly known as Sports Asylum, Inc. and changed its name to Cell MedX Corp. in September 2014. Cell MedX Corp. was incorporated in 2010 and is headquartered in Carson City, Nevada.
Stock data | 2023 | Change |
---|---|---|
Price | $0.035 | N/A |
Market Cap | $2.20M | N/A |
Shares Outstanding | 62.92M | 0.20% |
Employees | 0 | N/A |
Shareholder Equity | -2.39M | 18.74% |
Valuation | 2023 | Change |
---|---|---|
P/E Ratio | -3.50 | N/A |
P/S Ratio | 797.36 | N/A |
P/B Ratio | -0.92 | N/A |
Growth | 2023 | Change |
---|---|---|
Return on Equity | 0.2075 | N/A |
Earnings | 2023 | Change |
---|---|---|
Revenue | $2.76K | N/A |
Earnings | -$495.04K | N/A |
EPS | -0.01 | N/A |
Earnings Yield | -0.2857 | N/A |
Gross Margin | 0.1749 | N/A |
Operating Margin | -162.08 | N/A |
Net income margin | -179.23 | N/A |
Financial Strength | 2023 | Change |
---|---|---|
Total Assets | $103.27K | N/A |
Cash on Hand | $98.30K | N/A |
Debt to Equity | -1.0433 | 2.23% |
Current Ratio | 0.0415 | 105.78% |